Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Axogen

AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam

AxoGen (NASDAQ:AXGN) President and CEO Michael Dale said the company’s growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are expected to be positive but have not yet been quantified. Speaking during a company event, Dale said he w

AxoGen Stock Rockets 12% on Q1 2026 Revenue Beat, Raised Guidance and Debt-Free Balance Sheet

AxoGen Stock Rockets 12% on Q1 2026 Revenue Beat, Raised Guidance and Debt-Free Balance Sheet

AxoGen Inc. shares surged more than 11% on Tuesday, April 28, 2026, climbing to $43.98 in morning trading after the peripheral nerve repair company delivered a strong first-quarter revenue beat, posted adjusted profitability and raised its full-year 2026 guidance while announcing it had become debt-free following a successful public offering.

International Business Times

Axogen Smashes 52-Week High On FDA Nod For Breakthrough Nerve Repair Treatment

Axogen Smashes 52-Week High On FDA Nod For Breakthrough Nerve Repair Treatment

The U.S. Food and Drug Administration (FDA) on Wednesday approved Axogen Inc.’s (NASDAQ:AXGN) Biologics License Application for Avance, an acellular nerve scaffold for adult and pediatric patients aged 1 month or older with sensory, mixed, and motor peripheral nerve discontinuities.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

FDA Pushes Back Axogen Avance Nerve Graft Decision By 3 Months

The U.S. Food and Drug Administration (FDA) on Monday extended the Prescription Drug User Fee Act (PDUFA) goal date for Axogen Inc.’s (NASDAQ:AXGN) Biologics License Application (BLA) for Avance Nerve Graft by three months to December 5.

Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2022

12 Health Care Stocks Moving In Thursday's Intraday Session

Axogen: Q4 Earnings Insights

Axogen (NASDAQ:AXGN) reported its Q4 earnings results on Tuesday, February 22, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Axogen beat estimated earnings by 38.46%, reporting an EPS of $-0.08 versus an estimate of $-0.13.

inkl

Read news from The Economist, FT, and more,
with one subscription

1

Organisations

B of A Securities

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

Prescription Drug

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play